Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Other Non Operating Income (2019 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Other Non Operating Income for 3 consecutive years, with -$375000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Other Non Operating Income rose 46.2% year-over-year to -$375000.0, compared with a TTM value of -$2.2 million through Dec 2021, down 26.91%, and an annual FY2024 reading of $6.9 million, up 230.61% over the prior year.
  • Other Non Operating Income was -$375000.0 for Q4 2021 at Black Diamond Therapeutics, up from -$489000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $5.3 million in Q3 2019 and bottomed at -$5.3 million in Q2 2019.
  • Average Other Non Operating Income over 3 years is -$325500.0, with a median of -$456000.0 recorded in 2020.
  • Peak annual rise in Other Non Operating Income hit 92.02% in 2020, while the deepest fall reached 11716.67% in 2020.
  • Year by year, Other Non Operating Income stood at $6000.0 in 2019, then tumbled by 11716.67% to -$697000.0 in 2020, then surged by 46.2% to -$375000.0 in 2021.
  • Business Quant data shows Other Non Operating Income for BDTX at -$375000.0 in Q4 2021, -$489000.0 in Q3 2021, and -$584000.0 in Q2 2021.